Publication: A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand
1
Issued Date
2007-08-01
Resource Type
ISSN
10584838
DOI
Other identifier(s)
2-s2.0-34547094337
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Infectious Diseases. Vol.45, No.3 (2007), 308-314
Suggested Citation
Allen C. Cheng, Direk Limmathurotsakul, Wirongrong Chierakul, Nongluk Getchalarat, Vanaporn Wuthiekanun, Dianne P. Stephens, Nicholas P.J. Day, Nicholas J. White, Wipada Chaowagul, Bart J. Currie, Sharon J. Peacock A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clinical Infectious Diseases. Vol.45, No.3 (2007), 308-314. doi:10.1086/519261 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/24813
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand
Abstract
Background. Melioidosis is a tropical infectious disease associated with significant mortality. Most deaths occur early and are caused by fulminant sepsis. Methods. In this randomized, placebo-controlled trial, we assessed the efficacy of lenograstim (granulocyte colony-stimulating factor [G-CSF], 263 μg per day administered intravenously) in ceftazidime-treated patients with severe sepsis caused by suspected melioidosis in Thailand. Results. Over a 27-month period, 60 patients were enrolled to receive either G-CSF (30 patients, 18 of whom had culture-confirmed melioidosis) or placebo (30 patients, 23 of whom had culture-confirmed melioidosis). Mortality rates were similar in both groups (G-CSF group, 70%; placebo group, 87%; risk ratio, 0.81; 95% confidence interval, 0.61-1.06; P = .2), including among patients with confirmed melioidosis (83% vs. 96%; P = .3). The duration of survival was longer for patients who received G-CSF than for patients who received placebo (33 h vs. 18.6 h; hazard ratio, 0.56; 95% confidence interval, 0.31-1.00; P = .05). Conclusions. Receipt of G-CSF is associated with a longer duration of survival but is not associated with a mortality benefit in patients with severe sepsis who are suspected of having melioidosis in Thailand. We hypothesize that G-CSF may "buy time" for severely septic patients, but survival is more likely to be improved by management of associated metabolic abnormalities and organ dysfunction associated with severe sepsis. © 2007 by the Infectious Diseases Society of America. All rights reserved.